TMC647055
目录号 : GC13699丙型肝炎病毒NS5B聚合酶抑制剂
Cas No.:1204416-97-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
TMC647055 is a potent and selective non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase with EC50 value of 82 nM [1].
Hepatitis C virus (HCV) NS5B polymerase is a RNA-dependant RNA-polymerase that is responsible for viral replication and plays an important role in HCV life cycle. HCV is a major cause of chronic liver disease and acute hepatitis, ultimately leading to liver failure, cirrhosis and hepatocellular carcinoma [1].
TMC647055 is a selective and cell-permeating HCV NS5B inhibitor. In RNA polymerase primer-dependent transcription assay, TMC647055 inhibited HCV NS5B polymerase with IC50 value of 34 nM. In the Huh7-Luc cell line, TMC647055 inhibited the replication of genotype 1b replicon with EC50 values of 77 and 139 nM measured with luciferase readout and qRT-PCR readout, respectively. TMC647055 exhibited high-affinity interaction with NS5B across all genotypes (except for genotype 2b) with median KD value < 35 nM. In Huh7-Luc replicon cells, TMC647055 (750 nM) reduced 30 cell colonies formation. Also, TMC647055 (1.5 μM and 3.75 μM) reduced HCV replicon RNA [2] [3].
References:
[1]. Vendeville S, Lin TI, Hu L, et al. Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055. Bioorg Med Chem Lett, 2012, 22(13): 4437-4443.
[2]. Devogelaere B, Berke JM, Vijgen L, et al. TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage. Antimicrob Agents Chemother, 2012, 56(9): 4676-4684.
[3]. Cummings MD, Lin TI, Hu L, et al. Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem, 2014, 57(5): 1880-1892.
Cas No. | 1204416-97-6 | SDF | |
Canonical SMILES | CN(C(C(CN1C2=C(C(C3CCCCC3)=C41)C=CC(/C(O)=N/S5(=O)=O)=C2)=CC6=C4C=CC(OC)=C6)=O)CCOCCN5C | ||
分子式 | C32H38N4O6S | 分子量 | 606.73 |
溶解度 | ≥ 72.8mg/mL in DMSO with gentle warming | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.6482 mL | 8.2409 mL | 16.4818 mL |
5 mM | 0.3296 mL | 1.6482 mL | 3.2964 mL |
10 mM | 0.1648 mL | 0.8241 mL | 1.6482 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。